NMOSD trial success
…no relapse was observed in 58 patients over a median treatment duration of 73 weeks. NMOSD is a rare and devastating autoimmune disease that affects the central nervous system (CNS),…
Content Section: News Posts
…no relapse was observed in 58 patients over a median treatment duration of 73 weeks. NMOSD is a rare and devastating autoimmune disease that affects the central nervous system (CNS),…
Content Section: News Posts
…therapy. Professor John Hardy discussed how advances in sequencing and DNA chip technology are being used to identify different types of genetic risk for neurodegenerative diseases, thereby increasing understanding of…
Content Section: Conference Reports
…more recently realised. FEW investigations of late years have excited more interest than those which have been made into the connection of certain changes in the eye with diseases of…
Content Section: Articles
…student perspective as it gave a basic introduction to Encephalitis followed by more in-depth details of the disease, and was an excellent learning opportunity for the more junior audience members…
Content Section: Conference Reports
…the stimulation or suppression of activity in specific neuronal populations and circuits, they might prove a desirable replacement for deep brain stimulation in the treatment of Parkinson’s disease and depression….
Content Section: Articles
…during movement (e.g.looking directly at the limb which is moving) is significantly higher in patients with functional motor symptoms than neurological disease controls.3 In patients with functional motor symptoms, movement is…
Content Section: Articles
…Germany), a panel discussion on immunotherapy to treat Alzheimer’s disease, a poster session, and a moving and motivating address from the actor and Chancellor of the University of Ulster, James…
Content Section: News Posts
…mediated attack which causes intravascular haemolysis and platelet activation. This intravascular haemolysis is the hallmark of the disease and as well as being anaemic, patients can experience symptoms including haemoglobinuria,…
Content Section: Case Reports
…Tecfidera. Mechanism of Action Teriflunomide, a de novo pyrimidine synthesis inhibitor, is the primary metabolite of leflunomide which has been used worldwide as an oral disease modifying drug in the…
Content Section: Articles
© 2024 ACNR. Published by Whitehouse Publishing. Read our Privacy and Cookie Policy. Website by Sugar Web.
Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified.
For UK-based specialists, sign up for our journal mailing list.
URL here
You are now leaving the ACNR website, please click the "Continue" button below. If you do not wish to leave, please close this pop-up.